5 Papers
32 Citations
Liu Wei is an academic researcher from Centers for Disease Control and Prevention. The author has contributed to research in topics: Medicine & Randomized controlled trial. The author has an hindex of 4, co-authored 4 publications.
Chat about Author
Papers
HIV incidence, retention, and changes of high-risk behaviors among rural injection drug users in Guangxi, China
Liu Wei,Jie Chen,Michelle Rodolph,Geetha Beauchamp,Ben Mâsse,Rongjian Li,Shaoping Wang,Yuhua Ruan,Shizhu Liu,Li Zhang,Feng Zhou,Scott Rose,Thomas Perdue,Shenghan Lai,Yiming Shao,J. Brooks Jackson +15 more
TL;DR: HIV incidence is high among IDU in Guangxi, China despite a self-reported decrease in some high risk behaviors over the course of the Study, and changes in drug use and sexual behavior over a one year period.
24
Journal Article
Treatment efficacy of Lianhua Qingwen capsules for eraly-stage COVID-19.
TL;DR: Lianhua Qingwen Capsules can significantly improve the total effective rate for COVID-19 patients, as well as shorten the hospital stay and treatment time, which is worth of promotion in the clinic.
12
Prevalence and Seroincidence of Hepatitis B and Hepatitis C Infection in High Risk People Who Inject Drugs in China and Thailand
J. Brooks Jackson,Liu Wei,Fu Liping,Apinun Aramrattana,David D. Celentano,Louise Walshe,Yi Xing,Paul G. Richardson,Ma Jun,Geetha Beauchamp,Deborah Donnell,Yuhua Ruan,Liying Ma,David S. Metzger,Yiming Shao +14 more
TL;DR: The prevalence and incidence of HBV and HCV infection in people who inject drugs (PWIDs) at high risk for HIV in China and Thailand and the association with urine opiate test results and with short-term versus long-term buprenorphine-naloxone (B-N) treatment use in a randomized clinical trial are determined.
Are there adverse consequences of quizzing during informed consent for HIV research
Jeremy Sugarman,Amy Corneli,Deborah Donnell,Ting Yuan Liu,Scott Rose,David D. Celentano,Brooks Jackson,Apinun Aramrattana,Liu Wei,Yiming Shao,F Liping,R Baoling,B Dye,David S. Metzger +13 more
TL;DR: Quizzing during the informed consent process can be problematic for a minority of participants, and problems may be associated with the setting in which research takes place and educational level.
Expanding substance use treatment options for HIV prevention with buprenorphine-naloxone: HIV prevention trials network 058
David S. Metzger,Deborah Donnell,David D. Celentano,J. Brooks Jackson,Yiming Shao,Apinun Aramrattana,Liu Wei,Liping Fu,Jun Ma,Gregory M. Lucas,Marek C. Chawarski,Yuhua Ruan,Paul G. Richardson,Katherine Shin,Ray Y. Chen,Jeremy Sugarman,Bonnie J. Dye,Scott Rose,Geetha Beauchamp,David N. Burns +19 more
TL;DR: Participants receiving BUP/NX 3 times weekly were more likely to reduce opioid injection while on active treatment, and data support the use of thrice-weekly BUP-NX as a way to reduce exposure to HIV risk.